Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.
about
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyZidovudine and Lamivudine for HIV Infection.Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases.Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children.Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.Atriplatrade mark - HIV therapy in one pill.Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondriEmtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.Backbones versus core agents in initial ART regimens: one game, two players.A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.
P2860
Q33565604-031E319D-04BF-417C-9A54-6AF401A219F1Q34194561-51D3152D-E6AA-4AEE-ACDD-085B68D55DDEQ34483566-22801C92-7A06-43F5-A5EC-D2B67ADF823BQ35005470-80B58C03-B255-4963-9BF0-0C1B69B17EFFQ35214141-4B019BB9-D28C-4882-8066-FABE885B0321Q35609730-C4DFB9DA-C2D5-4DB5-8107-F3827B161962Q35903617-06907162-6AE6-4059-8DDB-BCF1323BD10DQ36103159-26DDF2CE-2A63-42F0-BF90-00A00C27683DQ36607380-893F1225-8865-46A2-9A28-F970720DC0C1Q36818184-3D47F8A9-ED11-4A9D-BA7A-581FC5A4F6A6Q36836868-24BBEDCA-D439-4BC0-8E4F-4AACA8096813Q37120519-458E09EE-3F52-4DB8-B5F5-F8375572C027Q38040137-18E2B8EC-AECA-428F-BDD8-C20B40514955Q38690825-0C9B778A-C077-44B9-8C80-074178939DDEQ40042881-F922E26F-752E-4292-A6FA-B60961EC021CQ40806577-D028AD06-8958-4FC2-8D90-CB9002D80D12Q42104125-7CFEC4C2-AA6C-417A-8DFA-6D05B1814EFDQ52374199-E0C227A3-19AF-40A9-A14E-59237D024A46Q54596202-E6DB8957-584E-4408-9E19-C110FA24FC34
P2860
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Prospective randomized trial o ...... iency virus-infected patients.
@en
Prospective randomized trial o ...... iency virus-infected patients.
@nl
type
label
Prospective randomized trial o ...... iency virus-infected patients.
@en
Prospective randomized trial o ...... iency virus-infected patients.
@nl
prefLabel
Prospective randomized trial o ...... iency virus-infected patients.
@en
Prospective randomized trial o ...... iency virus-infected patients.
@nl
P2093
P356
P1476
Prospective randomized trial o ...... iency virus-infected patients.
@en
P2093
Cary Moxham
Charles Wakeford
David W Barry
FTC-102 Clinical Trial Group
Franck S Rousseau
Herve Mommeja-Marin
Jeanette Harris
Joseph B Quinn
Laura Hulett
P304
P356
10.1086/379667
P407
P577
2003-10-31T00:00:00Z